Discovery Studio 3.1(2)

Discovery Studio 3.1
Discovery Studio life sciences modeling and simulation software incorporates the first commercially available software for predicting protein-protein aggregation to advance biotherapeutics research. In addition, a major update to the software’s 3D-molecular ActiveX control enables researchers to display dynamic molecular visualizations in webpages, Microsoft Office applications and Microsoft SharePoint collaboration software. The latest release includes the integration of a new algorithm licensed from Massachusetts Institute of Technology (MIT) that enables protein engineers to identify the size and location of regions on antibodies prone to aggregation and then predict mutations to improve formulation stability. Optimized for commercial use, the spatial aggregation propensity software provides significant time, cost and efficiency savings for research teams developing biological therapeutics by helping scientists rationalize aggregation effects and suggesting modifications to remedy the issue. By integrating the aggregation code into wider design workflows, scientists can make highly informed decisions on what changes to make without risking the stability or efficacy of the biologic.